Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share from the same period last year.